BiotechTube

Placebo + CT-388

Phase 2Active
1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Overweight or Obese

Conditions

Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)

Trial Timeline

Nov 21, 2024 → Nov 30, 2026

NCT ID
NCT06628362

About Placebo + CT-388

Placebo + CT-388 is a phase 2 stage product being developed by Roche for Overweight or Obese. The current trial status is active. This product is registered under clinical trial identifier NCT06628362. Target conditions include Overweight or Obese, Type 2 Diabetes Mellitus (T2DM).

What happened to similar drugs?

1 of 20 similar drugs in Overweight or Obese were approved

Approved (1) Terminated (0) Active (19)
✅AripiprazoleBristol Myers SquibbApproved
🔄Eloralintide + PlaceboEli LillyPhase 3
🔄Eloralintide + PlaceboEli LillyPhase 3
🔄Tirzepatide + PlaceboEli LillyPhase 3
🔄Tirzepatide + PlaceboEli LillyPhase 3
🔄Maridebart cafraglutide + PlaceboAmgenPhase 3
🔄Semaglutide + Semaglutide PlaceboNovo NordiskPhase 3

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06628362Phase 2Active
NCT06525935Phase 2Completed

Competing Products

20 competing products in Overweight or Obese

See all competitors
ProductCompanyStageHype Score
TERN-601Terns PharmaceuticalsPhase 2
32
LY3457263 + Tirzepatide + PlaceboEli LillyPhase 1
29
LY3305677 + PlaceboEli LillyPhase 1
29
LY3537031 + PlaceboEli LillyPhase 1
33
Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection)Eli LillyPhase 2
42
Eloralintide + PlaceboEli LillyPhase 3
47
LY4064912 + LY4064912 + Placebo + PlaceboEli LillyPhase 1
36
LY3437943 + Ethinyl Estradiol + DrospirenoneEli LillyPhase 1
29
Tirzepatide + AcetaminophenEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 2
39
Eloralintide + PlaceboEli LillyPhase 3
47
LY3437943 + PlaceboEli LillyPhase 1
29
LY3502970 + PlaceboEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 3
44
Eloralintide and Tirzepatide + EloralintideEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 3
40
LY3541105 + PlaceboEli LillyPhase 1
29
Retatrutide + PlaceboEli LillyPhase 2
35
LY4167586 + Placebo + LY4167586Eli LillyPhase 1
36
AZD9550 + AZD6234 + Placebo comparatorAstraZenecaPhase 2
39